Expression of C-50 antigen as a prognostic variable in transitional cell bladder tumours

Area of Science:

• Oncology
• Uropathology
• Biomarker Research

Background:

• Transitional cell carcinoma (TCC) of the bladder is a significant health concern.
• Accurate prognostic markers are crucial for effective bladder cancer management.
• The C-50 antigen's role as a prognostic indicator in bladder TCC requires further elucidation.

Purpose of the Study:

• To investigate the immunohistochemical expression of C-50 antigen in bladder tumors.
• To correlate C-50 antigen expression with clinicopathological parameters and patient outcomes.
• To assess the predictive value of C-50 antigen for tumor progression and survival.

Main Methods:

• Quantification of C-50 antigen expression using immunohistochemistry on 218 paraffin-embedded bladder tumor biopsy specimens.
• Correlation analysis between C-50 expression and tumor characteristics (T category, papillary status, WHO grade, DNA ploidy, S phase fraction).
• Long-term follow-up (over 10 years) to evaluate tumor progression (T, N, M categories) and patient survival using Cox's analysis.

Main Results:

• C-50 antigen expression showed an inverse correlation with T category, papillary status, and WHO grade.
• Aneuploid tumors with high S phase fraction exhibited low C-50 expression.
• Progression in T, N, and M categories was inversely correlated with C-50 expression.
• Low C-50 expression predicted progression in Ta-T1 tumors.
• C-50 expression was associated with a favorable prognosis in various subgroups, including papillary, diploid, WHO grade 2, and Ta-T1 tumors.
• Combined analysis of DNA ploidy and C-50 expression significantly predicted survival.

Conclusions:

• C-50 antigen expression is a valuable prognostic marker in transitional cell carcinoma of the bladder.
• Low C-50 expression is associated with aggressive tumor behavior and predicts progression, particularly in early-stage disease.
• The combination of C-50 expression and DNA ploidy offers a powerful tool for predicting patient survival.